OLOLADE IKUOMOLA: Open Payments
NPI 1114457421 · BALTIMORE, MD. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,784 in 110 payments from 24 companies in 2025. Trend: 2023 $2,360 · 2024 $1,505 · 2025 $1,784
Food & beverage: $1,784
| Company | Payments | Amount |
|---|---|---|
| Lilly USA, LLC | 18 | $320 |
| Novo Nordisk Inc | 10 | $172 |
| AstraZeneca Pharmaceuticals LP | 7 | $166 |
| ABBVIE INC. | 16 | $145 |
| PFIZER INC. | 18 | $141 |
| E.R. Squibb & Sons, L.L.C. | 7 | $128 |
| Dexcom, Inc. | 6 | $124 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 5 | $123 |
| Bayer Healthcare Pharmaceuticals Inc. | 3 | $78 |
| Phathom Pharmaceuticals, Inc. | 3 | $69 |
Products named: MOUNJARO, JARDIANCE, VRAYLAR, ELIQUIS, Dexcom G6 Transmitter, BREZTRI, CAMZYOS, Kerendia.
Industry payments across MD — which companies pay providers there.
